Back to Journals » Drug Design, Development and Therapy » Volume 9

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis

Authors Wu J, Zuo Y, Hu Y, Wang J, Li J, Qiao B, Jiang D

Received 1 December 2014

Accepted for publication 31 December 2014

Published 5 March 2015 Volume 2015:9 Pages 1359—1366

DOI https://doi.org/10.2147/DDDT.S78407

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Shu-Feng Zhou


Jun Wu,1 Yi Zuo,2 Yunjiu Hu,1 Jian Wang,2 Jidong Li,2 Bo Qiao,1 Dianming Jiang1

¹Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; ²Research Center for Nano-Biomaterials, Analytical and Testing Center, Sichuan University, Chengdu, Sichuan, People’s Republic of China

Abstract: The study was to develop and evaluate the rifapentine-loaded poly(lactic acid-co-glycolic acid) (PLGA) microspheres (RPMs) for the treatment of osteoarticular tuberculosis to avoid critical side effects caused by oral regimens of antibiotics or intravenous antibiotics. The RPMs were spherical with rough surfaces, and elevated amounts of rifapentine in the formulation markedly increased the particle size and drug loading, while decreased the size distribution and entrapment efficiency. The highest drug loading and encapsulation efficiency of RPMs were 23.93%±3.93% and 88.49%±8.49%, respectively. After the initial rapid drug release, the release rate gradually decreased, and approximately 80% of the encapsulated rifapentine was released after 30 days of incubation. Moreover, RPMs could effectively inhibit the growth of Staphylococcus aureus. With increasing rifapentine content, the inhibition zones were continuously enlarged while the minimal inhibitory concentration values decreased. These results suggested that RPMs were bioactive and controlled release delivery systems for the treatment of osteoarticular tuberculosis.

Keywords: Staphylococcus aureus, antitubercular drugs, in vitro, PLGA microspheres, chemotherapy, antibacterial

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]